Personalized chemotherapy for borderline resectable pancreatic cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This study tests whether tailoring chemotherapy drugs to your tumor's genetic signature helps treat borderline resectable pancreatic cancer (a type that sits between operable and inoperable). You'll receive chemotherapy before surgery, and the combination used will depend on specific markers found in your tumor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Diagnosed with borderline resectable pancreatic ductal adenocarcinoma (cancer that's partially attached to blood vessels) confirmed by imaging and expert review
- Biopsy of your pancreatic tumor must be available with sufficient cancer cells for genetic testing
- No prior chemotherapy, radiation, or surgery for pancreatic cancer (one cycle of a specific drug combination during waiting time is allowed)
- Good overall health and physical condition (WHO performance status 0–1)
- Adequate blood counts, liver, kidney, and heart function based on recent blood work and heart tracing
- Age 18–80 years old (ages 75–80 require special fitness evaluation)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a combination of three chemotherapy drugs (NALIRIFOX) given before surgery to shrink borderline resectable pancreatic cancer. The goal is to help make surgery more successful and improve outcomes.
This study tailors standard chemotherapy for pancreatic cancer based on whether the tumor has a change in the SMAD4 gene. The goal is to see if a specific treatment plan works better for each gene type.
This study is looking at genetic material and proteins from pancreatic tumors to understand how the cancer responds to treatment. It aims to help doctors choose the best therapies for patients with certain types of pancreatic cancer that can be removed surgically or that have not spread to other organs.
This trial tests a three-drug chemotherapy combination (gemcitabine, cisplatin, and nab-paclitaxel) given before surgery for people with pancreatic cancer that can be removed or is on the edge of being removable. The goal is to shrink the tumor and improve surgery outcomes.
This trial compares two chemotherapy regimens — GnP (gemcitabine and nab-paclitaxel) and mFOLFIRINOX — given in alternating cycles for people with borderline resectable pancreatic cancer. The goal is to see if this alternating approach can shrink the tumor enough to allow surgery.
This trial studies whether giving chemotherapy before surgery, and possibly adding a focused high-dose radiation treatment, can improve outcomes for people with borderline resectable pancreatic cancer. It aims to shrink or control the cancer and help more patients get to surgery safely.
Hear when a new Borderline Resectable Pancreatic Ductal Adenocarcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.